Dermatomyositis and polymyositis (myositis): vizsgálatok itt: Lengyelország
13 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 13.. Ask the study team whether a trial fits you.
- 1. fázisTaking peoplePhase IB open label, long-term, extension basket trial of RAY121 to inhibit classical complement pathway in immunological diseases (RAINBOW-LTE trial)
- Where
- Warsaw
- Életkor
- 18 év and over
- People
- 78 worldwide
- Run by
- Chugai Pharmaceutical Co. Ltd.
See details and how to join2024-511346-39-00 - 3. fázisNot yet taking people in LengyelországA Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
- Where
- Bialystok, Bydgoszcz, Katowice
- Életkor
- 18 év and over
- People
- 270 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07789015 · EU 2026-526365-24-00 - 3. fázisCsak meghívásosA Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
- Where
- Bydgoszcz, Lodz, Szczecin
- Életkor
- 18 év and over
- People
- 240 worldwide
- Run by
- argenx
See details and how to joinNCT05979441 · EU 2022-502851-79-00 - 1. fázisNot yet taking people in LengyelországA Study of BMS-986553 in Participants With Refractory Autoimmune Diseases
- Where
- Bydgoszcz, Krakow, Poznan
- Életkor
- 18 év and over
- People
- 60 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07873931 - 3. fázisTaking peopleA Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared with Placebo Added to Standard of Care in Adult Participants with Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
- Where
- Cracow, Lodz, Poznan, Warsaw, Wroclaw
- Életkor
- 18 év and over
- People
- 84 worldwide
- Run by
- AstraZeneca AB
See details and how to join2023-504022-19-01 - 3. fázisTaking peopleA Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
- Where
- Bialystok, Krakow, Lodz, Poznan, Warsaw, Wroclaw
- Életkor
- 18 év to 75 év
- People
- 240 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06455449 - 3. fázisTaking peopleA Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]
- Where
- Bialystok, Cracow, Poznan, Warsaw
- Életkor
- 18 év and over
- People
- 318 worldwide
- Run by
- Pfizer
See details and how to joinNCT05895786 · EU 2022-502739-20-00 - 3. fázisTaking peopleA Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies
- Where
- Bialystok, Cracow, Poznan, Warsaw
- Életkor
- 18 év and over
- People
- 211 worldwide
- Run by
- Pfizer
See details and how to joinNCT06698796 · EU 2024-514648-10-00 - 2. fázisTaking peopleAlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Where
- Bydgoszcz, Lodz, Warsaw
- Életkor
- 18 év and over
- People
- 90 worldwide
- Run by
- Artiva Biotherapeutics, Inc.
See details and how to joinNCT06991114 · EU 2025-520461-41-00 - 1. fázisTaking peoplePhase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
- Where
- Warsaw
- Életkor
- 18 év to 85 év
- People
- 144 worldwide
- Run by
- Chugai Pharmaceutical
See details and how to joinNCT06371417 · EU 2023-507692-21-00 - 1. fázisCsak meghívásosPhase 1b Long-term Extension Trial of RAY121 in Immunological Diseases (RAINBOW-LTE Trial)
- Where
- Warsaw
- Életkor
- 18 év to 85 év
- People
- 144 worldwide
- Run by
- Chugai Pharmaceutical
See details and how to joinNCT06723106 - 1. fázisTaking peopleA Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
- Where
- Bytom, Gdansk, Gliwice, Lodz
- Életkor
- 18 év and over
- People
- 125 worldwide
- Run by
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT07115745 · EU 2024-517681-41-00 - 1. fázisTaking peopleA Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
- Where
- Cracow, Poznan, Warsaw
- Életkor
- 18 év to 70 év
- People
- 44 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07371468 · EU 2025-522932-15-00